Diabetes Drug Shows Promise in Reducing Alzheimer's Disease

Alzheimer’s- lower levels of amylin

| Apr 16, 2014

In the United States, the Centers for Disease Control and Prevention (CDC) estimates that as many as half of all Americans who are alive today will end their lives in nursing homes, although it won’t be because their bodies cease to function, but because of their brains.

Degeneration of the brain – such as through memory loss, dementia, and loss of brain function – is one of the top causes of death in the U.S., ranked just behind heart disease and cancer by the CDC, and only a few places above diabetes.

A new study suggests that a drug used to treat diabetes shows promise in reducing the risk of Alzheimer’s.

Researchers at Boston University of School of Medicine (BUSM) found that Pramlintide, a relatively new drug used to treat both type 1 and type 2 diabetes, reduces the presence of amyloid-beta peptides, an amino acid that is present in higher levels in the brains of those with Alzheimer’s, and essentially toxic to nerve cells. The diabetes drug was also shown to help improve both learning and memory.

The drug is a synthetic version of amylin, a hormone that is released in conjunction with insulin by the pancreas and helps to slow the digestive process, lowering the risk of elevated blood glucose. It is approved for use by both type 1 and type 2 diabetics who use insulin.

In recognizing the link, researchers also found that those with Alzheimer’s had lower levels of amylin in their blood than those without Alzheimer’s, suggesting a new direction for the treatment and diagnosis of the disease.

There are currently more than 5 million people in the United States who have been diagnosed with Alzheimer’s, a disease that currently has no available treatment options.

Researchers are excited about the potential of Pramlintide for several reasons.

First, the drug is already on the market so it faces fewer hurdles than drugs that are in early stages of testing. Secondly, the drug’s key ingredients penetrate the brain, a necessary component of any drug used to treat the degenerative brain disease, and something that most drugs can’t do.

“Pramlintide can easily cross the blood/brain barrier and has shown a favorable safety profile for diabetes patients,” said the study’s lead author, Dr. Wendy Qiu, associate professor of Psychiatry and Pharmacology and Experimental Therapeutics at BUSM.

If clinical trials prove the effect of Pramlintide on Alzheimer’s, Qiu said the drug could be used to treat the disease in as little as three to five years.

The study appeared online in the journal Molecular Psychiatry. 

Click Here To View Or Post Comments

Categories: Amylin, Diabetes, Diabetes Health, Type 1 Diabetes, Type 2 Diabetes


Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • What's on the Horizon with Diabetes Research and Therapy
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Latest
Popular
Top Rated
Print | Email | Share | Comments (1)

You May Also Be Interested In...


Comments

Posted by Anonymous on 9 May 2014

Very promising! The finding that amylin and pramlintide may be active again Alzheimer's disease was actually first published by a group from Penn:
http://www.ncbi.nlm.nih.gov/m/pubmed/24239383/
The fact that two groups have shown this using different mouse models is a very promising sign.


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.